Body composition is associated with poor overall survival and accelerated time to progression in HCC patients treated with sorafenib. (September 2018) - Labeur, T.; van Vugt, J.; ten Cate, D.; Takkenberg, B.; Groot Koerkamp, B.; de Man, R.; van Delden, O.; IJzermans, J.; Eskens, F.; Klumpen, H.-J.